Clinical bottom line
Inhaled CXCR2 antagonists represent a putative targeted approach to managing neutrophilic inflammation in chronic obstructive pulmonary disease (COPD) exacerbations. Early-phase clinical studies suggest these agents may reduce neutrophil-driven airway inflammation, a key driver of exacerbation severity and frequency in a subset of COPD patients. However, current evidence remains preliminary, with limited data on long-term clinical outcomes, optimal patient selection, and comparative efficacy versus standard therapies. Clinicians should consider inhaled CXCR2 antagonists as an emerging, hypothesis-generating option pending further validation through rigorous randomized controlled trials.
What the evidence shows
COPD exacerbations are frequently characterized by neutrophilic airway inflammation, which contributes to tissue damage and symptom worsening (Chodosh et al., 2000). Traditional inhaled therapies, including corticosteroids, have variable efficacy in neutrophilic phenotypes, partly due to corticosteroid resistance in neutrophil-predominant inflammation (Baker et al., 2011). CXCR2, a chemokine receptor expressed on neutrophils, mediates their recruitment to inflamed airways, making it a rational therapeutic target.
Preclinical and early clinical data indicate that inhaled CXCR2 antagonists can reduce neutrophil influx and markers of airway inflammation in COPD models. Although large-scale phase 3 trials are lacking, smaller studies have demonstrated reductions in sputum neutrophils and inflammatory biomarkers, suggesting potential to mitigate exacerbation severity (Craddock et al., 2023). These agents may offer an alternative or adjunct to inhaled corticosteroids, particularly in patients with frequent neutrophilic exacerbations who respond poorly to standard anti-inflammatory treatments.
However, inhaled CXCR2 antagonists have not yet been shown to significantly reduce exacerbation frequency or improve lung function in broad COPD populations. The heterogeneity of COPD and the complexity of exacerbation triggers complicate interpretation of early results. Moreover, inhaled delivery may improve local airway targeting and reduce systemic side effects compared to oral CXCR2 antagonists, but data on inhalation device use and patient adherence remain limited (Craddock et al., 2023).
Caveats and uncertainty
The current evidence base for inhaled CXCR2 antagonists in COPD is limited by small sample sizes, short follow-up durations, and lack of robust clinical endpoints such as exacerbation rates or hospitalizations. Most studies focus on surrogate markers of inflammation rather than patient-centered outcomes. The heterogeneity of COPD phenotypes necessitates careful patient selection, as benefits may be confined to those with neutrophilic airway inflammation, which requires invasive or specialized testing to identify.
Additionally, the safety profile of inhaled CXCR2 antagonists requires further characterization. Potential risks include impaired host defense against infections due to neutrophil modulation. The impact of these agents in combination with established therapies such as long-acting bronchodilators and inhaled corticosteroids is not well defined. Furthermore, inhaler technique and adherence remain critical barriers to effective inhaled therapy delivery in COPD, as highlighted by Craddock et al. (2023).
How this may change practice
If ongoing and future trials confirm efficacy and safety, inhaled CXCR2 antagonists could become a valuable addition to the COPD treatment armamentarium, particularly for patients with frequent neutrophilic exacerbations unresponsive to current therapies. This would represent a move toward more personalized, phenotype-driven management of COPD exacerbations.
Clinicians should remain aware of the evolving evidence and consider enrolling eligible patients in clinical trials to further define the role of CXCR2 antagonists. Meanwhile, optimizing current inhaled therapies and addressing adherence barriers remain priorities. The potential for inhaled CXCR2 antagonists to reduce corticosteroid exposure and associated side effects is an attractive hypothesis warranting further investigation.